Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Combating antibiotic resistance: New drugs or alternative therapies?

Vanessa Hrvatin
CMAJ September 18, 2017 189 (37) E1199; DOI: https://doi.org/10.1503/cmaj.109-5469
Vanessa Hrvatin
Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Conversation about antibiotic resistance has been sparked again following a call by the World Health Organization (WHO) for new drugs to treat strains of gonorrhea resistant to available antibiotics.

An estimated 700 000 people die annually from infection with drug-resistant microbes, a figure that is projected to increase to about 10 million by 2050. Last year the United Nations declared antimicrobial resistance to be one of the biggest threats to global health. While there’s no disagreement that action must be taken to combat the evolving drug-resistance crisis, just how to proceed remains a matter of debate.

For some, the logical step forward is to develop new antibiotics. Earlier this year, a team of researchers at the University of Manitoba discovered a drug that could be used to treat many infectious organisms, including gonorrhea. The drug targets a sodium pump that functions in certain metabolic processes in pathogenic bacteria.

“The target of [the antibiotic] is novel … we are attacking a completely different aspect of bacterial viability,” said Grant Pierce, one of the researchers and the executive director of research at St. Boniface Hospital in Winnipeg.

Despite the potential of developing new antibiotics, it is likely that microbes will eventually become resistant to them as well. According to Pierce, however, this shouldn’t discourage research in the field.

“There is no reason why we shouldn’t test [new antibiotics] and use them, because bacteria are not resistant to them now, so it provides us nothing but good things,” he said.

Others, pointing out that new antibiotics will likely lead to more resistance, have called for innovation. That’s why Bob Hancock, professor of microbiology and immunology at the University of British Columbia, is developing solutions that aren’t focused on new antibiotics.

Figure1

WHO calls for new drugs to treat antibiotic-resistant gonorrhea strains.

Image courtesy of jarun011/iStock

“If we come up with new antibiotics, we’re still going to have those same pressures for development of resistance,” he said. “The drugs that we are producing today are just going to keep us in the game; they’re not going to get us ahead of the game. In my opinion, we need to change the game.”

Hancock is exploring the use of immune modulation therapy, host-directed therapy, and probiotics as means of circumventing the problem of antibiotic resistance. Probiotics look particularly promising, he said. A 2014 study in Italy, for example, found a “considerable reduction of episodes of both streptococcal and viral infections” in children prone to developing the infection after they were given probiotics as a preventative measure.

Some of the solutions Hancock envisions could act as alternatives to antibiotics; others would be adjuncts that improve the effectiveness of existing antibiotics.

“I don’t think we are abandoning anything. Instead, what we are doing is thinking of how we can take what we have right now and make it work better,” he said.

Whether the solution to treating drug resistant pathogens such as gonorrhea ends up being new drugs or alternative therapies, clinical application of either is likely years away. In the meantime, it is critical to develop diagnostic tests that identify pathogens reliably and quickly, so that appropriate targeted drug therapy can be given right away, said Hancock. He also noted that limiting the use of antibiotics in food-producing animals is important to tackling antibiotic resistance.

As for which approach to combating antibiotic resistance will ultimately prevail, that is still up for debate. “Time will tell which [new solutions] are best,” said Pierce. “My guess is that all of them will have varying degrees of success.”

Footnotes

  • Posted on cmajnews.com on Aug. 29, 2017.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (37)
CMAJ
Vol. 189, Issue 37
18 Sep 2017
  • Table of Contents
  • Index by author

Article tools

Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combating antibiotic resistance: New drugs or alternative therapies?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combating antibiotic resistance: New drugs or alternative therapies?
Vanessa Hrvatin
CMAJ Sep 2017, 189 (37) E1199; DOI: 10.1503/cmaj.109-5469

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Combating antibiotic resistance: New drugs or alternative therapies?
Vanessa Hrvatin
CMAJ Sep 2017, 189 (37) E1199; DOI: 10.1503/cmaj.109-5469
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Unpacking “long COVID”
  • Canada’s long road to a vaccine injury compensation program
  • Health advocates want help handling online harassment
Show more News

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire